




RealRate

PHARMACEUTICAL 2019

Neos Therapeutics Inc.
Rank 204 of 371



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai



PHARMACEUTICAL 2019

Neos Therapeutics Inc. Rank 204 of 371

The relative strengths and weaknesses of Neos Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Neos Therapeutics Inc. compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 155% points. The greatest weakness of Neos Therapeutics Inc. is the variable Other Expenses, reducing the Economic Capital Ratio by 153% points.

The company's Economic Capital Ratio, given in the ranking table, is -187%, being 144% points above the market average of -331%.

Input Variable	Value in 1000 USD
Assets, Current	88,678
Cost of Goods Sold	26,928
Intangible Assets	14,616
Liabilities, Current	57,105
Liabilities, Non-Current	46,407
Other Assets	149
Other Compr. Net Income	6.0
Other Expenses	53,107
Other Liabilities	0
Other Net Income	795
Property and Equipment	7,914
Research and Development	8,508
Revenues	49,988
Selling, General and Administrative Expense	13,915

Output Variable	Value in 1000 USD
Assets	111,357
Liabilities	103,512
Expenses	102,458
Stockholders Equity	7,845
Net Income	-51,675
Comprehensive Net Income	-51,672
Economic Capital Ratio	-187%

